Melanotan II: α-MSH Analog Pharmacology, Clinical History, and Safety Profile

Overview

Melanotan II (MT-II) is a synthetic cyclic heptapeptide analog of alpha-melanocyte-stimulating hormone (α-MSH) developed at the University of Arizona in the 1990s. It was originally investigated as a sunless tanning agent and for treatment of male erectile dysfunction. MT-II acts as a non-selective agonist at melanocortin receptors (MC1R, MC3R, MC4R, MC5R), producing skin pigmentation (MC1R), libido effects (MC3R/MC4R), and appetite suppression (MC4R).

Clinical History

Early-Phase Clinical Trials

MT-II was evaluated in Phase I and limited Phase II clinical trials. These trials reported induction of skin pigmentation (tanning) without UV exposure and, in male subjects, pro-erectile effects. The clinical development program was limited and did not proceed to registrational Phase 3 trials for either indication.

Bremelanotide (PT-141) Derivation

The pro-erectile effect of MT-II informed the development of bremelanotide (PT-141), a selective MC4R/MC3R agonist that received regulatory approval for female hypoactive sexual desire disorder (HSDD). The clinical investigation of MT-II thus contributed to the melanocortin field of sexual dysfunction therapeutics.

Safety Profile

MT-II has been associated with a range of adverse effects including nausea, flushing, spontaneous erections (priapism in some cases), mole darkening, and new-onset melanocytic lesions. Concerns have been raised about potential acceleration of melanoma and the appearance of new atypical nevi. These safety concerns, together with the lack of regulatory approval, contributed to the discontinuation of formal clinical development.

Regulatory Status

Melanotan II is not approved by the FDA, EMA, or other major regulatory authorities for any indication. It is sold through unregulated channels, and regulatory agencies have issued warnings against its use outside of clinical trials. The substance is prohibited by the World Anti-Doping Agency (WADA).

Evidence Assessment

MT-II has a documented early-phase clinical evidence base supporting its pharmacological effects (pigmentation, erectile function), but no registrational clinical trials and a concerning safety profile. It is included in this library for scientific and historical documentation within the melanocortin peptide class. This compound is not approved for human therapeutic use.